Guangdong Taienkang Pharmaceutical Co., Ltd. Class A

Guangdong Taienkang Pharmaceutical Co., Ltd. Class A

SSZSE:301263
17.75
CNY
-0.24
(-1.33%)
0.02EPS
333.72P/E
9.75BMarket Cap
Apr 29Next Earn

Total Valuation

CNY

As of September 30, 2026, Guangdong Taienkang Pharmaceutical Co., Ltd. Class A carries a market capitalization of 9.75B, placing it among publicly traded companies globally. Its enterprise value stands at 9.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap9.75B
Enterprise Value9.84B

Important Dates

Guangdong Taienkang Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 29, 2027.

Earnings Date4/29/2027

Share Statistics

As of September 30, 2026, Guangdong Taienkang Pharmaceutical Co., Ltd. Class A has 510.60M shares outstanding.

Shares Outstanding510.60M

Valuation Ratios

As of September 30, 2026, Guangdong Taienkang Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 333.72. The price-to-sales ratio is 14.05, and the price-to-book ratio stands at 6.52.

PE Ratio333.72
PS Ratio14.05
PB Ratio6.52
P/TBV Ratio11.91

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 14.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 9.84B versus a market cap of 9.75B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales14.43

Financial Position

As of September 30, 2026, Guangdong Taienkang Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.46, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.75, indicating elevated leverage, while an interest coverage ratio of -0.94 demonstrates limited ability to service its debt obligations.

Current Ratio1.46
Quick Ratio0.78
Debt / Equity38.75
Debt / EBITDA-38.09
Interest Coverage-0.94

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 590,774.33 in revenue per employee across its workforce of 1,154.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee590,774.33
Employee Count1,154.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Guangdong Taienkang Pharmaceutical Co., Ltd. Class A recorded an income tax benefit of -29.08M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -18.37M and 28.71M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-29.08M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Guangdong Taienkang Pharmaceutical Co., Ltd. Class A's stock has declined approximately 30.69% over the past 52 weeks. The 50-day moving average sits at 19.21, while the 200-day moving average is 21.53.

52-Week Price Change-30.69%
50-Day Moving Average19.21
200-Day Moving Average21.53

Income Statement

CNY

Over the twelve months ended September 30, 2026, Guangdong Taienkang Pharmaceutical Co., Ltd. Class A generated 681.75M in revenue and converted that into 28.71M in net income, yielding earnings per share of 0.02. EBITDA reached -15.83M, while operating income came in at 692,369.94.

Revenue681.75M
Gross Profit383.14M
Operating Income692,369.94
Pretax Income-18.37M
Net Income28.71M
EBITDA-15.83M
EBIT-15.83M
Earnings Per Share (EPS)0.02

Balance Sheet

CNY

As of September 30, 2026, Guangdong Taienkang Pharmaceutical Co., Ltd. Class A holds 572.81M in cash and equivalents against 603.06M in total debt, resulting in a net debt position of 113.39M. Total book value stands at 1.49B, with working capital of 341.60M providing operational flexibility.

Cash & Cash Equivalents572.81M
Total Debt603.06M
Net Debt113.39M
Equity (Book Value)1.49B
Book Value Per Share2.93
Working Capital341.60M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-139.70M

Margins

Over the twelve months ended September 30, 2026, Guangdong Taienkang Pharmaceutical Co., Ltd. Class A posted a gross margin of 56.20, reflecting its pricing power and cost economics. The operating margin of 0.10 and net profit margin of 4.21 provide insight into operational efficiency.

Gross Margin56.20
Operating Margin0.10
Pretax Margin-2.69
Profit Margin4.21
EBITDA Margin-2.32

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Guangdong Taienkang Pharmaceutical Co., Ltd. Class A paid dividends of 0.06 per share. The dividend payout ratio of -436.59 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.18, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Guangdong Taienkang Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.06
Payout Ratio-436.59
Shareholder Yield0.18

Stock Splits

Guangdong Taienkang Pharmaceutical Co., Ltd. Class A's most recent stock split took place on June 1, 2026 with a 5:6 split ratio.

Last Split Date6/1/2026
Split Ratio5:6

Scores

As of September 30, 2026, Guangdong Taienkang Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 6.39, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.39